6th Apr 2021 09:16
(Alliance News) -Â Clinigen Group PLC said it will be providing access to Erwinase in the UK from Tuesday.
This is part of the global exclusive licensing and distribution agreement with Porton Biopharma announced a year ago.
Erwinase is approved in the UK as a component of a chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukaemia who have developed hypersensitivity to E. coli-derived asparaginase.
Erwinase is manufactured by Porton Biopharma and Clinigen is responsible for marketing, packaging, labelling, storage and distribution.
With the onboarding of Erwinase coming earlier than anticipated, said Clinigen, this will bring forward an expected investment in working capital in line with previous guidance of GBP10 million to GBP20 million. Given the proximity to the year end and staggered roll out across each territory, however, this is not expected to have a material impact on current year profit expectations.
"Erwinase is an important treatment option for healthcare professionals in the UK and this represents a major milestone since partnering with PBL. PBL has invested in enhancing its manufacturing to increase Erwinase capacity and our ongoing focus is to ensure effective future supply in the UK and in other international markets where patients need access," said Clinigen Chief Operating Officer Sam Herbert.
Clinigen shares were up 0.3% at 800.50 pence in London on Tuesday.
By Lucy Heming;Â [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L